日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Safety and Efficacy of Lucitanib Plus Toripalimab in Advanced Solid Tumors Refractory to Standard Therapies: An Open-Label, Multicenter, Phase II Study

Lucitanib联合Toripalimab治疗对标准疗法耐药的晚期实体瘤的安全性和有效性：一项开放标签、多中心、II期研究

期刊:MedComm
影响因子:10.7
doi:10.1002/mco2.70672
Zhou, Ting; Sun, Haishuang; Chen, Gang; Zhang, Guoping; Wu, Jinsheng; Qu, Shenhong; Han, Yaqian; Hu, Desheng; Ling, Yang; Zheng, Yulong; Liu, Jian; Lin, Lizhu; Li, Yongsheng; Pan, Jianji; Liu, Yanyan; Wang, Cuiying; Fu, Guohong; Feng, Jian; Shi, Jianhua; Cai, Huiming; Li, Meng; Li, Fugen; Wang, Yinbin; Zhang, Li; Yang, Yunpeng
发表日期：2026
文献求助 收藏

A multicenter, open-label, single-arm, phase Ib clinical trial of HH2853 treatment in patients with relapsed and/or refractory peripheral T-cell lymphoma

一项针对复发和/或难治性外周T细胞淋巴瘤患者的HH2853治疗的多中心、开放标签、单臂Ib期临床试验

期刊:Journal of Hematology & Oncology
影响因子:40.4
doi:10.1186/s13045-025-01697-z
Hong, Huangming; Chen, Zegeng; Zhang, Mingzhi; Peng, Zhigang; Shen, Jianzhen; Shuang, Yuerong; Zhou, Hui; Guo, Hongqiang; Huang, He; Li, Fei; Qian, Zhengzi; Liu, Lihong; Wang, Liang; Yang, Wei; Zhang, Liling; He, Pengcheng; Qian, Shen; Li, Fugen; Li, Meng; Lin, Tongyu
T细胞
淋巴瘤
T细胞
细胞生物学
免疫/内分泌
发表日期：2025
文献求助 收藏

Safety and efficacy of HH2853, a novel EZH1/2 dual inhibitor, in patients with refractory solid tumours or non-Hodgkin lymphomas: a phase I study

新型 EZH1/2 双重抑制剂 HH2853 在难治性实体瘤或非霍奇金淋巴瘤患者中的安全性和有效性：一项 I 期研究

期刊:EClinicalMedicine
影响因子:10
doi:10.1016/j.eclinm.2025.103398
Fan, Zhengfu; Wang, Jin; Liu, Dan; Shen, Lin; Fang, Meiyu; Johnson, Patrick; Tun, Han; Sommerhalder, David; Yang, Jilong; Yang, Yun; Munozi, Javier; Zhu, Jun; Gao, Tian; Li, Zhiming; Li, Xian'an; Ma, Qiuying; Lv, Chao; Yu, Songda; Li, Fugen; Song, Yuqin; Gong, Jifang
淋巴瘤
EZH1
发表日期：2025
文献求助 收藏

Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with MET exon 14 skipping mutated non-small cell lung cancer

GLORY 研究的长期随访结果：一项针对携带 MET 14 号外显子跳跃突变的东亚非小细胞肺癌患者的古马隆替尼 II 期研究

期刊:Translational Lung Cancer Research
影响因子:3.5
doi:10.21037/tlcr-2025-638
Lu, Shun; Yu, Yongfeng; Zhou, Jianya; Li, Xingya; Goto, Koichi; Min, Xuhong; Nishino, Kazumi; Cui, Jiuwei; Wu, Ling; Sakakibara, Jun; Shu, Yongqian; Dong, Xiaorong; Li, Lu; Yoneshima, Yasuto; Zhou, Chengzhi; Li, Xiaoling; Zhang, Yiping; Huang, Dingzhi; Zang, Aimin; Zhang, Wei; Wang, Xiuwen; Zhang, Li; Bai, Chong; Fang, Jian; Cao, Lejie; Zhao, Yanqiu; Yu, Yan; Shi, Meiqi; Zhong, Diansheng; Li, Fugen; Duanmu, Wenhao; Wang, Yibin
肺癌
肿瘤
肿瘤免疫
细胞生物学
MET
发表日期：2025
文献求助 收藏

A pooled analysis of clinical outcome in driver-gene negative non-small cell lung cancer patients with MET overexpression treated with gumarontinib

对接受古马隆替尼治疗的MET过表达驱动基因阴性非小细胞肺癌患者的临床结果进行汇总分析

期刊:Therapeutic Advances in Medical Oncology
影响因子:4.2
doi:10.1177/17588359241264730
Yu, Yongfeng; Dong, Wen; Shi, Yanxia; Wu, Rong; Yu, Qitao; Ye, Feng; Zhou, Chengzhi; Dong, Xiaorong; Li, Xingya; Li, Yongsheng; Li, Zhen; Wu, Lin; Pan, Yueyin; Shen, Hong; Wu, Dehua; Xu, Zhongyuan; Wu, Jinsheng; Xu, Nong; Qin, Yanru; Zang, Aimin; Zhang, Jingdong; Zhou, Jianya; Zhang, Xiaotao; Zhao, Yanqiu; Li, Fugen; Wang, Huizhen; Liu, Qi; Han, Zhenyong; Li, Jin; Lu, Shun
肺癌
肿瘤
肿瘤免疫
细胞生物学
MET
发表日期：2024
文献求助 收藏

A novel technique for NO.253 lymph node dissection and left colic artery preservation to avoid potential postoperative internal hernia in laparoscopic radical resection for rectal cancer

一种用于腹腔镜直肠癌根治术中253号淋巴结清扫和左结肠动脉保留的新技术，可避免术后潜在的内疝。

期刊:BMC Surgery
影响因子:1.8
doi:10.1186/s12893-024-02492-2
Luo, Wenjun; Li, Fugen; Qian, Chuan; Lu, Tingting; Xiao, Yanling; Xu, Zhengwen; Jia, Yingdong
肿瘤
肠癌
肿瘤免疫
发表日期：2024
文献求助 收藏

Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial

古马隆替尼治疗携带MET 14号外显子跳跃突变的非小细胞肺癌患者：一项多中心、单臂、开放标签的1b/2期试验

期刊:EClinicalMedicine
影响因子:10
doi:10.1016/j.eclinm.2023.101952
Yu, Yongfeng; Zhou, Jianya; Li, Xingya; Goto, Koichi; Min, Xuhong; Nishino, Kazumi; Cui, Jiuwei; Wu, Lin; Sakakibara, Jun; Shu, Yongqian; Dong, Xiaorong; Li, Lu; Yoneshima, Yasuto; Zhou, Chengzhi; Li, Xiaoling; Zhang, Yiping; Huang, Dingzhi; Zang, Aimin; Zhang, Wei; Wang, Xiuwen; Zhang, Li; Bai, Chong; Fang, Jian; Cao, Lejie; Zhao, Yanqiu; Yu, Yan; Shi, Meiqi; Zhong, Diansheng; Li, Fugen; Li, Meng; Wu, Qiuxia; Zhou, Jun; Sun, Minghui; Lu, Shun
肺癌
肿瘤
肿瘤免疫
细胞生物学
MET
发表日期：2023
文献求助 收藏

Benchmarking the Human Leukocyte Antigen Typing Performance of Three Assays and Seven Next-Generation Sequencing-Based Algorithms

对三种检测方法和七种基于新一代测序的算法进行人类白细胞抗原分型性能基准测试

期刊:Frontiers in Immunology
影响因子:5.9
doi:10.3389/fimmu.2021.652258
Liu, Ping; Yao, Minya; Gong, Yu; Song, Yunjie; Chen, Yanan; Ye, Yizhou; Liu, Xiao; Li, Fugen; Dong, Hua; Meng, Rui; Chen, Hao; Zheng, Aiwen
细胞生物学
Human
发表日期：2021
文献求助 收藏

Establishment and characterization of 38 novel patient-derived primary cancer cell lines using multi-region sampling revealing intra-tumor heterogeneity of gallbladder carcinoma.

利用多区域取样建立和表征 38 个新的患者来源原代癌细胞系，揭示胆囊癌的肿瘤内异质性

期刊:Human Cell
影响因子:3.1
doi:10.1007/s13577-021-00492-5
Feng Feiling, Cheng Qingbao, Li Bin, Liu Chen, Wang Huizhen, Li Bin, Xu Xiaoya, Yu Yong, Chen Zishuo, Wu Xiaobing, Dong Hua, Chu Kaijian, Xie Zhenghua, Gao Qingxiang, Xiong Lei, Li Fugen, Yi Bin, Zhang Dadong, Jiang Xiaoqing
细胞生物学
肿瘤
肿瘤免疫
发表日期：2021
文献求助 收藏

Predicted CD4(+) T cell infiltration levels could indicate better overall survival in sarcoma patients

预测的CD4(+) T细胞浸润水平可能预示着肉瘤患者的总体生存率更高。

期刊:Journal of International Medical Research
影响因子:1.5
doi:10.1177/0300060520981539
Bi, Qing; Liu, Yang; Yuan, Tao; Wang, Huizhen; Li, Bin; Jiang, Ye; Mo, Xingkui; Lei, Yonghong; Xiao, Yanbin; Dong, Suwei; Shen, Hongmei; Lv, Li; Yang, Yihao; Dong, Hua; Wang, Jing; Li, Fugen; Zhang, Dadong; Ai, Yiqin; Lin, Jie
T细胞
T细胞
细胞生物学
CD4
免疫/内分泌
发表日期：2021
文献求助 收藏